Xenotransplantation is frequently used to study normal and malignant hematopoiesis of human cells. However, conventional mouse xenotransplantation models lack essential human-specific bone-marrow (BM)-microenvironment-derived survival, proliferation, and self-renewal signals for engraftment of normal and malignant blood cells. as a consequence, many human leukemias and other hematologic disorders do not robustly engraft in these conventional models. Here, we describe a complete workflow for the generation of humanized ossicles with an accessible BM microenvironment that faithfully recapitulates normal BM niche morphology and function. the ossicles, therefore, allow for accelerated and superior engraftment of primary patient-derived acute myeloid leukemia (aMl) and other hematologic malignancies such as myelofibrosis (MF) in mice. the humanized ossicles are formed by in situ differentiation of BM-derived mesenchymal stromal cells (Mscs). Human hematopoietic cells can subsequently be transplanted directly into the ossicle marrow space or by intravenous injection. using this method, a humanized engraftable BM microenvironment can be formed within 6-10 weeks. engraftment of human hematopoietic cells can be evaluated by flow cytometry 8-16 weeks after transplantation. this protocol describes a robust and reproducible in vivo methodology for the study of normal and malignant human hematopoiesis in a more physiologic setting.
IntroDuctIon
Xenotransplantation is currently the only reliable assay that facilitates the functional definition of human hematopoietic stem cells (HSCs) and their malignant counterparts, leukemia stem cells. Xenotransplantation is therefore instrumental in developing a detailed understanding of human hematopoiesis and leukemogenesis. Humanized mouse models have become an important tool for the investigation of normal and malignant human hematopoiesis [1] [2] [3] , and progressively more immune-deficient mice strains have been developed to improve engraftment of hematopoietic cells [4] [5] [6] [7] [8] . Furthermore, mice with human cytokine overexpression or knock-in into the endogenous mouse loci have been engineered to further enhance human engraftment [9] [10] [11] [12] [13] [14] [15] .
Although other xenotransplantation models are fairly advanced and can recapitulate many aspects of normal human hematopoiesis, several major limitations remain to be overcome in regard to the engraftment of malignant cells. A substantial proportion of samples from patients with primary AML, in particular those from less aggressive clinical subtypes such as those bearing mutations in core binding factor (CBF) and those classified as acute promyelocytic leukemia (APL), failed to engraft in NOD/SCID/IL2R-gamma null (NSG) mice or did so at low levels that do not mimic clinical human disease [16] [17] [18] . Furthermore, other more chronic hematopoietic neoplasms completely lacked engraftment in all of the available mouse strains and attempt to generate xenograft models of myelodysplastic syndrome, myeloproliferative neoplasms, and multiple myeloma met with limited success [19] [20] [21] .
The reasons for the difficulty in xenotransplantation of some human hematopoietic neoplasms remain largely unclear, but they probably relate to the lack of cross-reactivity of specific factors and environmental clues that mediate hematopoietic cell homing, survival, and expansion. Human hematopoiesis is regulated by a specialized microenvironment, the BM niche 22 . This specialized microenvironment is necessary to fully recapitulate human disease in vivo by providing survival and maintenance signals to hematopoietic stem and progenitor cells (HSPCs) and leukemiainitiating cells that actively contribute to proper hematopoietic and disease development 23, 24 . These signals include the following: (i) secreted species-specific cytokines, chemokines, and growth factors and (ii) the direct interaction of hematopoietic cells with microenvironmental stromal cells such as MSCs and extracellular matrix. To overcome these limitations, we recently developed a novel xenotransplantation system that generates heterotopically localized bone organoids (hereafter defined as ossicles)-niches in mice to mimic the aforementioned human-specific microenvironmental signals. Using this system, we were able to successfully engraft the majority of AML samples, including CBF-driven leukemias and APL. Furthermore, this novel approach could be used for the first time to formally identify disease-initiating cells in human primary MF and APL 25 .
This protocol is based on this recently published work and provides step-by-step, user-friendly, reproducible instructions for the generation and subsequent use of such humanized microenvironments. Generation of BM-MSC-derived humanized ossicles will allow investigators to more successfully and faithfully perform xenotransplantation experiments.
We describe the following: (i) isolation and expansion of BMderived MSCs using a xenoprotein-free cell culture system; (ii) transplantation and generation of subcutaneously localized humanized ossicles in NSG mice; (iii) subsequent transplantation of normal or malignant hematopoietic cells into generated Generation and use of a humanized bone-marrowossicle niche for hematopoietic xenotransplantation into mice ossicles; and, finally, (iv) engraftment analysis of ossicle and other hematopoietic tissues in ossicle-bearing mice. Collectively, this comprehensive protocol allows for the reproducible generation of immune-compromised mice bearing humanized BM microenvironments that will lead to superior engraftment of normal and leukemic human hematopoietic cells, thereby providing an ideal tool to better recapitulate and model human hematopoietic development and hematopoietic malignancies in vivo. We anticipate that this technology will contribute substantially to disease understanding and development of novel therapeutic approaches in the future.
This method has been successfully used in our investigations 25, 26 , and other investigators have generated similar ectopic humanized marrow organs using different protocols ( Table 1) and also showed superior leukemia engraftment as compared with naive mice, further supporting the hypothesis that a humanized BM microenvironment is beneficial for the growth of human leukemia cells 27, 28 . Our humanized microenvironment was also sufficient to promote the engraftment of hematopoietic cells differentiated from AML-derived induced pluripotent stem (iPS) cells 26 .
Application of the method
The humanized BM ossicle xenotransplantation system can be used to study healthy and malignant human hematopoietic cells in a humanized BM microenvironment that more faithfully recapitulates physiological settings. In addition to providing a favorable microenvironment for human hematopoietic engraftment, direct intraossicle transplantation of hematopoietic cells into the ossicle marrow space minimizes the substantial cell loss usually experienced after intravenous application and therefore allows for transplantation of lower cell numbers that will still enable robust engraftment. Importantly, disease-initiating cell frequencies within leukemia subpopulations can be studied and have been shown to be substantially higher using this xenotransplantation system as compared with alternative NSG xenotransplantation models 25 . Engraftment of cell populations with low engraftment potential can be augmented by injecting cells into multiple ossicles in the same mouse (Fig. 1a) .
Our model also allows investigation of homing and migration of transplanted cells to other humanized niches when cells are injected by the intraossicle route into only one (out of four) ossicle of an individual mouse (Fig. 1b) , or can be used to study homing of injected cells to humanized sites in comparison with mouse BM if cells are injected intravenously (Fig. 1c) . Moreover, the humanized ossicle model is not restricted to investigation of human hematopoietic cell engraftment; it might also be a valuable tool for studying bone metastasis behavior of solid tumors that exhibit poor metastasis behavior in conventional xenotransplantation models (Fig. 1d) . Table 1 summarizes the major alternative methods. Many of these methods use osteoconductive scaffold materials such as tricalcium phosphate/hydroxyapatite, biphasic calcium phosphate (BCP), or medical-grade polycaprolactone (mPCL) to form heterotopic bone constructs to mimic a BM microenvironment in vivo. Such methods require in vitro precoating of these materials with naive or predifferentiated BM-MSCs to force the cells into a preosteoblast state 27, [29] [30] [31] [32] [33] . Another approach is based on time-consuming in vitro manufacturing of late hypertrophic cartilage templates (with and without the use of collagen-based scaffold material) to generate ossicles that are then seeded with hematopoietic tissue to mimic physiological endochondral bone formation when implanted into immune-compromised mice 30, [34] [35] [36] [37] . Both strategies require laborious cell culture to generate transplantable scaffolds or tissue, followed by surgical implantation of the in vitro-generated tissue into subcutaneous pockets on the flanks of mice. By contrast, our protocol does not rely on osteoconductive scaffold material, in vitro predifferentiation, and surgical implantation. Following our protocol, in vitro-expanded cells are simply injected into the subcutaneous space, spontaneously undergo differentiation in situ, and form a humanized BM microenvironment through endochondral ossification, a process recapitulating the normal development of the hematopoietic niche 38, 39 . The simple subcutaneous injection reduces surgery-induced morbidity and allows for the generation of many more experimental mice per time compared with time-consuming surgical implantation.
Comparison with other methods

Experimental design Isolation and expansion of BM-MSCs (Steps 1-25).
Working with the optimal cellular material is key for the generation of proper human ossicles. BM was found to be the only source of MSCs with the inherent capacity to spontaneously undergo endochondral ossification and form an in situ BM microenvironment seeded with hematopoietic cells when injected into a heterotopic subcutaneous location 38, 39 . For the successful recapitulation of this protocol, we recommend the use of pooled human platelet lysate (pHPL) as media supplement instead of FBS for the isolation and expansion of human BM-MSCs 27,31,40-42 , as we and others have recently shown that pHPL is highly efficient for expanding MSCs and is even superior to FBS for stimulation of cell proliferation [43] [44] [45] [46] . Therefore, using pHPL in BM-MSC cell culture will allow faster generation of the cell quantities necessary for transplantation into mice. Several other independent reports also suggest that pHPL-expanded MSCs can be successfully used to generate humanized BM in vivo 27, 31, [40] [41] [42] (for a comprehensive comparison of the different protocols, see Table 1 ). We recommend producing pHPL by matching platelets of blood group O with plasma of blood group AB to avoid possible influences of ABH antigens and isoagglutinins (see Box 1 for pHPL production details) [46] [47] [48] .
MSCs should be isolated by means of plastic adherence, and initial plating of mononuclear cells (MNCs) should be done at frequencies between 5,000 and 10,000 MNCs per cm 2 cell culture area 46 . This will optimize the outgrowth of countable, individually separable colony-forming unit fibroblasts (CFU-Fs). Freshly prepared BM aspirates (Step 1, option A) or filter washouts collected from BM-harvest equipment (Step 1, option B) can be used as the starting material. We previously demonstrated that MSCs can be very efficiently isolated from unmanipulated BM (no lysis, no BM-MNC enrichment through density centrifugation) 46 After initial outgrowth of CFU-Fs, adherent cells should be passaged and further expanded in appropriate-sized cell culture flasks at cell seeding densities between 100 and 1,000 cells per cm 2 . The cell culture surface area required for the expansion of MSCs depends on the final cell number needed to generate the intended number of ossicles. We recommend using 225-cm 2 flasks for cell Sublethal irradiation
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(continued) isolation (passage (p)0), followed by a change to multilayered cell factories (CF-4s) thereafter (p1 and later). To increase successful ossicle formation rates, we recommend using only early-passage MSCs (no older than 20-25 population doublings, corresponding to p1-p4), as these cells have a higher proliferative index.
Backup cells from early passages should be cryopreserved in liquid nitrogen to guarantee sufficient material for repetitive experiments (Fig. 2a) . Allogeneic and autologous (with respect to transplanted hematopoietic cells) MSCs can be used for xenotransplantation assays.
Cell characterization (Steps 10-17).
Criteria for the identification of MSCs from human BM include their fibroblast-like morphology combined with immunophenotypic characterization.
Proper flow-cytometric quality control must be performed to ensure MSC purity and integrity 49 . A small number of extra cells should be expanded for immunophenotypic profiling in parallel to the large-scale expansion of cells that will be used for the generation of ossicles (Fig. 2b) . One day before the in vivo transplantation is planned, these extra cells should be harvested by trypsin digestion and stained with antibodies, as described in Table 1 . Isotype-matched control antibodies should be used to exclude nonspecific staining, and 7-aminoactinomycin D (7-AAD) should be used to evaluate cell viability. Flow-cytometric analysis should show that isolated BM-MSCs are positive (>95%) for CD90, CD73, and CD105, but that they lack expression (<2%) of hematopoietic markers, including CD45 (panleukocyte marker), CD34 (HSPC and endothelial cell marker), CD14 or CD11b (macrophage and monocyte markers), CD79-á or CD19 (B-cell markers), and HLA-DR (Fig. 2b) 49 . Although the absence of the described hematopoietic markers can exclude contamination with hematopoietic cells, expression of CD90, CD73, and CD105 is not specific to MSCs and unfortunately does not predict their functionality. Generally, cell-surface immunophenotypes are highly overlapping between MSCs isolated from various tissue sources 38 and can change during in vitro culture 50 . of an increase in marrow cavity size 25 . Transplanted MSCs will spontaneously differentiate into chondrocytes and subsequently undergo endochondral ossification to form a humanized BM microenvironment 38, 39, 41 . The time course of this differentiation process should ideally be evaluated for each individual BM-MSC donor to estimate the ideal time point to start hematopoietic cell transplantations 38 . Usually, ossicle BM cavities start to develop 6-8 weeks post MSC injection, and they should be fully developed after a maximum of 10 weeks. This time frame is in line with other reports using BM-MSC coated, surgically implanted scaffold materials to generate humanized hematopoietic niches 27, 33 . Appropriate marrow cavity formation can be indirectly evaluated by screening the ossicles (after shaving the areas of injection) for a color change from white/yellowish to purple, which indicates the presence of mouse hematopoietic tissue within the developing ossicle ( Fig. 3b and Supplementary Video 2). Despite their morphologic and immunophenotypic similarities in vitro, we observed an inherent variability in the ability to generate robust ossicles when transplanting BM-MSCs in vivo from different donors. Using AML patient-derived BM stromal cells,
Transplantation of BM-
Box 1 | Pooled human platelet lysate production: • tIMInG 10 d
Platelet-derived growth factors efficiently stimulate cell proliferation in vitro. This effect has been reported for mesenchymal stromal cells (MSCs), fibroblasts, and endothelial colony-forming cells 25, 44, 45, 48, 67 . BM-MSCs isolated and expanded using pHPL, replacing FBS, conserve their endochondral ossification capacity and reliably form humanized ossicles in vivo. One unit of platelet lysate (PL) is produced from one unit of platelet concentrate derived from four BC units and one plasma unit (five blood donors in total); see also supplementary Figure 1. Ten PL units are then pooled to make one batch of pooled human platelet lysate (pHPL) (supplementary Fig. 1) . So, for one PL unit, the materials described in the following procedure are needed. additional reagents • 4 units of whole blood, blood group O, collected into a citrate-phosphate-dextrose-containing quadruple-bag system • 1 unit of whole blood, blood group AB, collected into a citrate-phosphate-dextrose-containing quadruple-bag system procedure 1. Take five units of regular whole-blood donations (450 ± 50 ml each, one unit of blood group (BG) AB and four units of BG O) collected into a citrate-phosphate-dextrose-containing quadruple-bag system (e.g., by Fresenius HemoCare) derived from five healthy blood donors after written informed consent. Cool the blood bag systems to 20-24 °C.
 pause poInt The blood can be kept at 22 ± 2 °C for up to 24 h until further processing.
2. Centrifuge the whole quadruple-bag system for 13 min at 4,250g at 22 °C for sedimentation of platelets to the BC layer together with leukocytes. 3. Separate the fraction of RBCs and the plasma supernatant from the middle BC portion by transfer into the respective satellite bags. Disconnect the RBC and plasma bags from the BC bag by sterile welding (supplementary Fig. 1a ). 4. Mix four BC units (derived from BG O donors; each unit represents an individual donor) with one unit of plasma (BG AB donor) in a 600-ml plasma bag and centrifuge the mixture for 6 min at 340g at 22 °C. 5. Transfer the supernatant to a platelet-storage bag and deplete the leukocytes via inline filtration to obtain one unit of leukocytedepleted platelet concentrate. 6. Freeze leukocyte-depleted platelet concentrate units at −30 °C for at least 48 h to fragment the platelets and release growth factors. 7. Repeat steps 1-6 until ten platelet concentrate units are collected (supplementary Fig. 1b) .  crItIcal step Do not proceed until all ten platelet concentrate units have been collected to prepare a well-standardized product guaranteeing appropriate growth factor concentrations 45 . 8. Thaw ten units of leukocyte-depleted platelet concentrate in a water bath at 37° until the ice clots disappear. The product is now called human platelet lysate (HPL). Do not warm the HPL. 9. Connect the HPL bags consecutively and transfer the HPL to a pooling double bag and transfer the HPL. Disconnect the individual HPL bags by welding. 10. After mixing all ten units together, pool the final volume of 2-3 liters, now called pooled HPL (pHPL), and divide it into aliquots of smaller-size bags (e.g., 200 ml) or 50-ml conical tubes for storage. Mixing of the units can be perfomred at room temperature (RT; 22-25 °C). 11. Freeze-thaw pHPL an additional time to increase the rate of platelet fragmentation and the amount of released growth factors and transfer the pHPL from 200-ml bags to 50-ml conical tubes for storage. Pooled HPL at this stage can be stored at -20 to -30 °C for up to 7 d. 12. Remove the platelet fragments from the pHPL through centrifugation at 4,000g (15 min, 4 °C).  crItIcal step This step is very important, as platelet fragments aggregate during cell culture. 13. Pipette the supernatant plasma into the final storage containers (50-or 15-ml conical tubes) and discard the platelet pellets. 14. Freeze aliquoted pHPL at −20 °C (supplementary Fig. 1c) .  crItIcal step A sterility check of the final product must be performed before using the pHPL for cell culture. For sterility release criteria, we recommend including negative testing for bacteria, fungi, and mycoplasma.
 pause poInt pHPL can be frozen at −20 °C for up to 3 years before use. we could see sufficient ossicle formation in 44% (8/18) of the tested samples (Fig. 4) . Insufficient in vivo differentiation and marrow infiltration can lead to organoids with reduced marrow formation and only small areas of hematopoietic infiltration (Fig. 4 , middle panel). Some BM-MSC donors are incapable of in vivo marrow formation (Fig. 4, right panel) . Therefore, we recommend evaluating in vivo endochondral ossification and marrow cavity formation from three to five individual donors on a smaller scale before initiating comprehensive experiments. Only donors that result in robust ossicle formation with intact marrow infiltration (Fig. 4 , left column) should be used for further studies.
Transplantation of normal and malignant hematopoietic cells into humanized ossicles (Steps 40-47).
Before transplanting human hematopoietic cells, ossicle-bearing mice must be conditioned with a sublethal dose of irradiation (200 rad). It is hypothesized that this opens the hematopoietic niches for incoming human hematopoietic cells. Alternative conditioning regimens such as busulfan chemotherapy [55] [56] [57] have not been tested in our model, but they might facilitate elimination of radiation-induced damage to the niche and could extend the use of the humanized ossicle model to investigators without access to animal irradiation. The humanized BM ossicle model allows the direct injection of human cells into a humanized microenvironment, thereby circumventing the substantial cell loss seen in intravenous transplantations (Figs. 1a,b and 2e and Supplementary Video 2). Using a 29-gauge insulin needle, application of slight pressure and drilling movements will result in penetration of the cortical bone structure of the ossicle, subsequently allowing for the infusion of hematopoietic cells, including sorted human HSPCs or subfractions, T-cell-depleted bulk leukemia cells, or sorted leukemia subpopulations in a volume not exceeding 20 µl. Proper localization of the needle within the ossicle should be tested by aspiration before infusing the cells. Slight withdrawal of the plunger should result in aspiration of marrow visible within the syringe that will be reintroduced along with the transplanted cells (Supplementary Videos 2 and 3) . If the experimental goal is to achieve maximal engraftment, all four ossicles can be transplanted (Fig. 1a) , but if migration to other ossicles is intended, only one ossicle should be used for transplantation (Fig. 1b) . Alternatively, cells can be injected intravenously into mice carrying humanized ossicles (Fig. 1c) .
Evaluation of human engraftment in humanized ossicles and mouse BM and peripheral blood (Step 48 and onward). The easily accessible subcutaneous localization of the humanized ossicles allows for serial monitoring of hematopoietic engraftment by ossicle aspirations. We recommend intervals of at least 2 weeks between aspirations in order to minimize inaccurate engraftment assessments due to damage caused by prior aspirations. To guarantee reproducible engraftment measurements from aspirates, we recommend combining two individual aspirates from the two opposite poles of one ossicle. This should normalize for potential geographic differences of engraftment within individual ossicles. The extent of engraftment is determined by flow cytometry (Fig. 5) with an antibody panel designed to detect human lymphoid (B cells, T cells) and myeloid cells (monocytes and granulocytes). To permit gating out of contaminating mouse leukocytes and erythrocytes, we typically add antibodies that detect these populations, such as mouse CD45 and mouse Ter119 (Fig. 5a) .
Limitations of the method
Although bone, cartilage, and MSCs within the ossicle BM microenvironment are of human origin, the vasculature and the developing BM sinusoidal structures are mouse-derived. This will probably limit the applicability of the model to addressing questions involving human-specific niche factors associated with the endosteal and perivascular, but not the endothelial, niche. In our studies, all humanized ossicles are conditioned using sublethal irradiation to increase human normal and leukemic engraftment. Unfortunately, irradiation-based conditioning procedures significantly damage the BM niche and will therefore influence studies of HSC regulation by the
Step 41
Step 42
Step humanized microenvironment. Alternative conditioning regimens, which are less toxic to the niche, such as antibodybased approaches [58] [59] [60] or feeding mice amino acid-deficient diets 61 , could be explored to deplete hematopoietic elements.
Furthermore, ossicles could be generated in genetically engineered mice such as NSG W41 mice that allow engraftment without irradiation to circumvent issues of conditioninginduced niche toxicity 62, 63 .
MaterIals
REAGENTS
Human BM aspirates or BM collection bag filters, acquired per institutional protocol. Samples for this study were obtained according to Administrative Panel on Human Subjects Research Institutional Review Board (IRB)-approved protocols (Stanford IRB nos. 18329, 6453, and no. 5637) with informed consent ! cautIon Working with material collected from human subjects IRB approval. Human specimens must be collected with the informed consent of the donors. Fresh or frozen human umbilical cord blood (UCB) for transplantation into ossicles acquired per institutional protocol. For this study, cord blood was collected with written informed consent from the mother, which was obtained before delivery of full-term pregnancies at the Lucile Packard Children's Hospital according to IRB-approved protocols (Stanford IRB no. 5637) ! cautIon Working with material collected from human subjects requires IRB approval. Human specimens must be collected with the informed consent of the donors.  crItIcal Fresh or frozen UCB or BM MNCs, as well as enriched CD34+ HSPCs, are commercially available from different vendors or can be sourced from full-term deliveries per institutionally approved protocols. In the latter case, collection and preparation of MNCs, as well as CD34 + HSPC enrichment using MACS technology protocols should be performed as previously described by Park et al. 64 Enrichment of CD34 + cells is recommended to minimize FACS sorting time for HSPC purification before transplantation. After MACS-based enrichment, typical yields are >90% purity with 30-50% recovery. FACS-sorted HSPC subfractions should yield >99% purity. Frozen primary leukemia samples acquired per institutional protocol. Samples for this study were obtained according to Administrative Panel on Human Subjects Research Institutional Review Board (IRB)-approved protocols (Stanford IRB nos. 18329, 6453, and 5637) with informed consent. ! cautIon Primary leukemia samples should be collected only after obtaining the patient's informed consent following IRB-approved protocols. Primary patient material should be handled according to institutional biosafety protocol requirements. Alpha-modified minimum essential medium (a-MEM; Sigma-Aldrich, cat. no. M4526) RPMI 1640 medium, l-Glutamax-supplemented + HEPES (Thermo Fisher Scientific, cat. no. 72400047) Heparin (1,000 U/ml; Fresenius-Kabi, cat. no. 63323-540-57) l-Glutamax, 100× (200 mM; Thermo Fisher Scientific, cat. no 25-030-081) Penicillin-streptomycin (10,000 U/ml; Thermo Fisher Scientific, cat. no. 15-140-122) 40 buffy coat (BC) units derived from regular whole-blood donations of blood group O 10 plasma units derived from regular whole-blood donations of blood group AB  crItIcal Human BC units and human plasma can be sourced from various vendors or should be obtained after informed consent from healthy volunteer blood donors fulfilling legal requirements for blood donation. We obtain our human BC units and plasma from collaborating partners from the Department of Blood Group Serology and Transfusion Medicine, Paracelsus University, Salzburg, Austria. Figure 1 for details of how to produce pHPL. Stromal cell culture medium Supplement 500 ml of a-MEM with 5 ml of l-Glutamax, 5 ml of penicillin-streptomycin, 2 U/ml heparin, and 50 ml of O/AB pHPL (10% (vol/vol); see Box 1 and Supplementary Figure 1 for production details). Heparin should be added to the medium before pHPL supplementation to avoid gel formation. Before use, the supplemented a-MEM should be sterile-filtered through a 0.22-µm bottle filter. The medium should be stored at 4 °C until required and can be used for up to 2 weeks. Repeated filtration might be necessary to get rid of newly formed particles. BM harvesting medium Supplement 500 ml of RPMI1640 medium with 5 ml of l-Glutamax, 5 ml of penicillin-streptomycin, and 10% (vol/vol) FBS. Store the medium at 4 °C for a maximum of 2 weeks. Before use, add 2 U/ml heparin and 20 U/ml DNase I. BM collection medium Prepare 50 ml of PBS containing 10 mM EDTA (final), and prepare 500-µl aliquots in microcentrifuge tubes. The medium can be stored at room temperature (RT; 22-25 °C) for up to 3 months. Cell staining medium (FACS buffer) Add 2% FBS (vol/vol) and 2 mM EDTA to 500 ml of PBS. Mix the contents well and sterile-filter through a 0.22-µm filter bottle. Store the medium at 4 °C and use it within 1 month. BM-MSC cryopreservation medium Add 10% DMSO (vol/vol) to stromal cell culture medium,; store the medium at 4 °C and use it within 2 weeks.
2% Dextran solution Dissolve 1 g of dextran in 50 ml of ddH 2 O.
Filter the solution through a 0.2-µm filter. 2% (wt/vol) dextran should be stored at 4 °C and can be used for up to 1 year. Human HSPC antibody cocktail We usually mix all lineage antibodies (see 'Reagents' list above), resulting in a master mix that reduces pipetting error and can be used to stain multiple samples. Typically, we use all lineage antibodies (CD2, CD3, CD4, CD7, CD8, CD16, CD19, CD20, CD56, CD235a, and CD14) at a 1:50 final dilution in FACS buffer (except CD235a, which is included at a dilution of 1:200). However, optimal antibody concentration should be determined empirically by the investigator before use. Antibodies for CD34, CD38, CD45RA, and CD90 are added individually, with a final concentration ranging from 1:25 to 1:50, but the optimal concentration should be determined empirically by each investigator. In our experience, up to 1 × 10 7 UCB HSPCs can be stained in a total volume of 50 µl of staining buffer. Store the human HSPC antibody cocktail at 4 °C in the dark. Do not use the staining master mix for longer than a week. Human engraftment antibody cocktail Prepare a staining master mix by combining all human engraftment antibodies (list provided in 'Reagents' above) before adding them to the cells. Antibody dilutions range from 1:25 to 1:200 (final), but optimal antibody concentrations should be determined empirically and may vary between different antibody lots and antibody providers. In our experience, up to 1 × 10 7 cells can be stained in a total volume of 50 µl of staining buffer. Store the cocktail at 4 °C in the dark. Do not store or use the staining master mix for longer than a week. Extracellular matrix Thaw Angiogenesis Assay extracellular matrix solution and the diluent overnight at 4 °C. Precool 1,000-µl pipette tips and 14-ml round-bottom tubes on ice before use to limit matrix loss due to sticking to the inside of the tips while pipetting. We recommend pipetting in a cold room (if available). Add 110 µl of diluent to 1 ml of extracellular matrix solution and mix well by pipetting up and down while trying to avoid generation of air bubbles. Prepare at least 300 µl of extracellular matrix per single MSC injection to account for the inevitable matrix loss during pipetting. The final volume of extracellular matrix solution per single injection will be only 240 µl, as the remaining volume (to make a total 300-µl injection volume) comes from 2 × 10 6 MSCs resuspended in 60 µl of precooled pHPL. Leftover mixed diluted extracellular matrix solution should be used within 1 week.  crItIcal Angiogenesis Assay Kit (extracellular matrix) components should be kept at 4 °C to avoid solidifying.  pause poInt At this point, MSCs can be cryopreserved, and the frozen cells can be used later for expansion. To freeze the cells, pellet them by centrifugation at 300g for 7 min at 4 °C and resuspend them in a freezing medium before dividing them into aliquots of 5 × 10 5 to 1 × 10 6 cells in cryovials (1 ml per vial) and place the cryovials into a slow-freeze cryovial chamber in a −80 °C freezer. Transfer the vials to liquid nitrogen the following day.
7| Seed 500 cells per cm 2 in one or multiple CF-4s (2,528 cm 2 each) using 400 ml of freshly prepared stromal cell culture medium per CF-4. Total cells needed per CF-4 are 1,264,000 (= 500 × 2,528). Liquids within CF-4s are distributed between individual layers by placing the closed cell factory onto its long side, which carries the smaller port. The larger-size vent cap should be on top. Wait until the fluid levels within the layers equilibrate before turning the CF-4 to the short side so that the ports are oriented up and distribute the medium to cover the whole surface area.  crItIcal step To avoid uneven seeding of cells due to unlevel incubator shelves, we highly recommend checking that the incubator is exactly level before starting large-scale expansion in a CF-4.  crItIcal step If you are using frozen cells, thaw a frozen aliquot of early-passage cells and pre-expand them in a T225 flask before seeding into CF-4s as described in Step 13.
8|
Seed an extra T75 flask at 1,000 cells per cm 2 for MSC characterization by flow cytometry (Fig. 2b) .  crItIcal step These cells will be harvested and analyzed for MSC marker expression before harvesting the CF-4s.
9|
Replace one-third of the culture medium twice weekly until the cells reach confluence. 2c for full gating strategy). Export FCS files to generate histograms, as shown in Figure 2b using FlowJo or other third-party software confirming MSC purity and integrity. MSCs at this stage should be >95% positive for CD73, CD90, and CD105, and should lack (<2%) expression of CD45, CD14, HLA-DR, CD19, and CD34 (Fig. 2b) 49 .  crItIcal step Cells should be injected into mice only if expanded BM-MSCs meet the criteria described above.
Immunophenotypic characterization of Mscs
Harvesting of expanded cells from cF-4s
• tIMInG 2-3 h 18| Confirm confluence of BM-MSCs grown in CF-4s by microscopy before starting the harvesting procedure.
19| Pour out stromal cell culture medium from the smaller port into a 500-ml, 0.22-µm-pore-size bottle filter and keep the filtered medium for quenching TrypLE Express.
20|
Wash the cells by carefully adding 150 ml of prewarmed PBS.
 crItIcal step When carrying CF-4s to and from incubators, always carry with the ports upward to prevent liquids moving from one layer to another.
21|
After removing PBS, add 70 ml of prewarmed TrypLE. Distribute it between layers as described in Step 7 and incubate it for 7 min at 37 °C to lift the cells. 22| Gently tap the CF-4 and quench the TrypLE by adding 150 ml of filtered medium that was collected in Step 19.
23|
Collect the cells in a 500-ml centrifuge bottle and wash the CF-4 once more with 150 ml of filtered medium to collect the remaining cells. Alternatively, the cells can be collected in multiple 50-ml conical tubes and the pellets can be combined after being resuspended individually.
24| Spin down at 300g at 4 °C for 7 min, aspirate the medium and resuspend the pellet in a maximum of 12 ml of filtered medium.  crItIcal step Carefully weigh the collection bottles to be able to accurately balance the centrifuge. 
25|
28|
Use precooled 1,000-µl pipette tips to add 240 µl of extracellular matrix solution (prepared as described in Reagent Setup) per 2 × 10 6 MSCs (e.g., 5.28 ml for 44 × 10 6 BM-MSCs) and mix well by pipetting up and down. Avoid using serological pipettes for this step.
29|
Keep the cell-matrix mix on ice until injecting into mice. Cells can be kept on ice for up to 2 h.  crItIcal step Minimize the production of air bubbles during resuspension, and keep the cell-matrix mix on ice at all times. 30| Anesthetize mice using isoflurane (2%, oxygen flow rate: 2 liters/min) and carefully shave both flanks with clippers.
31|
Clean the sites of injection twice using 70% EtOH wipes (use fresh wipes each time).
32| Draw 300 µl of the cell-matrix mix from Step 29 into 25-gauge Monoinject syringes.
33|
Punch the mouse skin on the flank and then lift the needle to confirm subcutaneous localization. Lifting the needle additionally helps generate a pouch that allows for easy deposition of the cell-matrix mix.
34|
Slowly apply the 300-µl cell-matrix mix and remove the needle. Compress the site of the skin puncture for 10 s with sterile forceps to minimize backflow.
35|
Repeat Steps 31-34 to inject up to four sites per animal.
36|
Put the animals into a clean cage placed under a heat source (red light) for recovery. Place the mice on clean paper towels to avoid asphyxiation. After recovery (usually within a minute), put the mice back into their original cages.
37|
Starting from day 3 post MSC transplantation, subcutaneously inject (into dorsal neck fold) the transplanted mice daily with human 1-34 PTH. Use 50 µl of 20 µg/ml PTH (= 40 µg/kg of body weight (BW) of a 25-g mouse) for 28 consecutive days. PTH injections are not mandatory for proper ossicle formation but significantly increase the size 25 . These cells should be left on ice, in the dark before they are analyzed and/or sorted. (v) Define human HSPCs based on the expression of CD34, CD38, CD90, CD45RA, and CD123 (Fig. 6a) (Fig. 6b) on a FACSAria II or another three-laser machine with a similar laser setup.  crItIcal step It is very important to avoid contamination of the transplant with mature CD3 + T cells, as T cells can proliferate in NSG mice and potentially cause fatal Xeno-GvHD.  crItIcal step If the blast count within primary samples exceeds 90%, or if FACS sorting is not possible, contaminating donor T cells can be eliminated using immunomagnetic microbead technologies. We usually perform CD3 enrichment and take the depleted cell fraction for transplantation using EasySep reagents (see Reagents list).
(viii) Sort the cells into microcentrifuge tubes containing cold staining buffer with PI. Typically, >90% purity can be reached with a single sort. To increase the purity to >99%, we usually perform a double sort.  crItIcal step For all experiments, verify the purity of the sorted population by reanalyzing a small fraction of the collected cells.
(ix) Spin down the cells for 7 min at 300g at 4 °C and aspirate the staining buffer. 
42|
Localize the ossicle and fix it between the thumb and the index finger (Fig. 2) 43| Punch the needle through the skin and subcutaneous tissue until reaching the bony surface of the ossicle.
44|
By applying pressure and a back-and-forth motion, use the tip of the needle to drill a whole into the cortical shell of the ossicle. When the needle goes through the bone layer, a slight relief can be noticed. If performed appropriately, the syringe should be fixed in the ossicle at this point.
45|
Aspirate with a slight withdrawing pressure to confirm proper localization of the needle within the hematopoietic tissue in the humanized marrow cavity. If the needle is in the right position, a tiny drop of blood should become visible in the syringe when aspirating.
46|
Slowly inject the cells into the marrow cavity of the ossicle over 10-15 s.  crItIcal step Injection volumes >20 µl, injecting too fast, or injecting air bubbles can lead to respiratory stress, embolism, and possibly death. 47| Clearly mark injected mice by punching their ears (or use similar methods) and label cage card with location of the injected ossicles.
evaluation of short-term engraftment from ossicles (weeks 6-8)
• tIMInG 4-6 h  crItIcal For further details of how to carry out Steps 49-51, watch supplementary Video 3.  crItIcal As an alternative to this section, individual ossicles can be surgically removed and prepared for analysis, as described in Steps 62-65 at various time points, following institutional guidelines for surgical procedures.
48| At 6-8 weeks after hematopoietic cell transplantation, anesthetize and prepare mice by following Steps 30 and 31, before performing an ossicle BM aspiration with an empty 29-gauge insulin syringe from the ossicle, as described in Steps 42-44.  crItIcal step Precoat the syringe walls with EDTA-containing BM collection buffer to prevent coagulation.
49|
Aspirate the hematopoietic cells from the ossicle (use maximal withdrawing pressure) by quickly pulling the plunger of the syringe. If the needle was placed correctly in the ossicle BM cavity, this will lead to the appearance of a tiny visible drop of ossicle marrow in the syringe. An average ossicle BM aspirate should yield 2-4 µl of marrow.  crItIcal step Occasionally, needles can become clogged while drilling through the bone, making it impossible to aspirate BM from the ossicle marrow cavity. A clogged needle will lead to a scenario in which the plunger moves back to its initial position after pulling out. In the rare case of a clogged needle, we recommend repeating the aspiration with a fresh precoated syringe.
? trouBlesHootInG 50| Transfer the aspirated hematopoietic cells to a prelabeled microcentrifuge tube filled with 500 µl of BM-collection buffer (Reagent Setup) and mix thoroughly.
51|
Repeat Steps 49 and 50 on the opposite ossicle pole and combine both aspirates to account for geographical differences in engraftment levels.  pause poInt The ossicle aspirates can be left at RT for up to 3 h while performing aspirations on additional ossicle sites and animals.
52|
If you plan to compare human engraftment between humanized ossicle niches and the murine peripheral blood and/or murine BM, additionally collect peripheral blood (at least five drops) and/or perform a BM aspirate from the mouse femur using institutionally approved protocols for femur marrow collection and tail bleed sampling. A video protocol showing femur collection has been previously published 64 .
53|
Transfer the ossicle marrow aspirated from microcentrifuge tubes to 5-ml round-bottom tubes and fill them with 3 ml of precooled staining buffer.
54|
Spin the tubes for 7 min at 300g at 4 °C to pellet the cells.
55|
Resuspend the cells with 500 µl of RBC lysis buffer and incubate them for 5 min on ice.
56| Fill the tubes with precooled staining buffer and centrifuge for 7 min at 300g at 4 °C to pellet the cells.
57|
Aspirate the supernatant without disrupting the cell pellet, such that 25 µl of buffer is left in the FACS tube.
58|
To reduce nonspecific Fc-receptor-mediated antibody binding, block the cells by adding 2.5 µl of Fc blocking reagent, mix well, and incubate the cells for 5-10 min at RT. It is not necessary to wash the cells between blocking and antibody staining. 63| Surgically remove the ossicles individually. Cut the mouse skin ~5-10 mm from the ossicle and clear the subcutaneous space using sterile scissors. After localizing the ossicle, carefully excise it from its surrounding connective tissue using a sterile scalpel. Crush the ossicle using a mortar and pestle in 3 ml of BM harvesting medium.  crItIcal step For crushing, do not apply too much force, as this can reduce cell viability. Gentle disruption of the ossicle is particularly important when working with fragile engrafted human primary leukemia samples.
64|
Filter the cells through a cell strainer snap cap and incubate the tubes for 10 min in a 37 °C water bath to allow for sufficient digestion by DNase.
65|
Spin down the mixture for 7 min at 300g at 4 °C, and wash an additional time by filling the FACS tube with precooled staining buffer.
66|
Resuspend the cell pellet in 300 µl of FACS buffer and keep the cells on ice. 67| If human engraftment will be compared between humanized ossicle niches and the murine peripheral blood and/or murine BM, additionally harvest the cells from mouse peripheral blood (option A) and/or mouse BM (option B). 
69| If desired, cryopreserve aliquots of the remaining cells from
Step 66 using the cell freezing medium, or use the remainder for secondary transplantation as described in Park et al. 65 If secondary transplantation into ossicles is planned, careful timing of the experiments is important to having new ossicle-bearing mice available at the time of sacrificing the primary recipients.
The completion of our outlined protocol (including time for in vivo ossicle formation and long-term hematopoietic engraftment, but not including optional secondary transplantation) takes 28-32 weeks. We typically freeze multiple aliquots of early-passage BM-MSCs (p0 or p1). Subsequently, frozen cell aliquots are expanded in CF-4s for large-scale production of cells before subcutaneous MSC transplantation. Using fresh BM-MSCs is not recommended for comprehensive experiments, as endochondral ossification potential should be pre-evaluated on a small scale for each new, fresh donor. Harvesting of BM-MSCs and transplanting of MSCs into NSG mice must be performed on the same day. Therefore, we recommend only generation of a maximal number of cells sufficient to transplant 30 mice. Harvesting and transplantation of more mice is not recommended, as delay in transplanting the BM-MSCs might negatively affect ossicle formation. Inexperienced users should 
antIcIpateD results
Carefully following the steps provided in our protocol should result in the generation of high numbers of proliferative BM-derived stromal cells, which will readily form individual CFU-Fs in the initial isolation step and thereafter can be extensively expanded to generate sufficient cells for preparing BM-MSC transplants. If nonadherent cells are removed as suggested and adherent stromal cells are properly passaged for further expansion, our resulting cell population usually meets required immunophenotypic criteria (Fig. 2) . Culture in large multilayered tissue culture vessels guarantees sufficient expansion, and the expected cell number per CF-4 (2,528-cm 2 cell surface area) should reach between 60 and 80 × 10 6 BM-MSCs, which will be enough material for up to ten mice if four ossicles are injected per animal. After subcutaneous implantation, the injection site will initially have a soft bump because of the volume injected, which will reduce in size over the first few days post injection (Fig. 2) . Careful palpation of the transplants can be performed and should confirm progressive transformation of the tissue into a more rigid subcutaneous lump over a time course of 1-3 weeks post transplantation. We confirmed by histological analysis that these palpable changes in tissue stiffness can be attributed to early chondrogenic differentiation followed by progressive tissue remodeling reminiscent of endochondral ossification 38 . Later in the development of the humanized BM ossicle niche, a continuous change of color should be visible when carefully examining the developing subcutaneous ossicle in shaved mice. This transformation from a whitish/yellow to a purple hue is indicative of an increasing infiltration of the developing BM microenvironment with murine hematopoietic tissue (Fig. 2) . When a suitable BM donor, capable of endochondral ossification and marrow formation, has been identified (Fig. 3, left panel) , 75-95% of transplanted sites should form adequately sized ossicles that are suitable to be used for direct intraossicle transplantation of human hematopoietic cells after 6-10 weeks (supplementary Video 2). After conditioning irradiation, direct intraossicle injection of as few as 100 human HSPCs should lead to robust multilineage short-term (6-8 weeks) and long-term engraftment (16 weeks) in the injected ossicle (Fig. 5c) , but it will eventually also lead to mobilization with subsequent homing and engraftment at distant human ossicles. As seen in naive NSG mice without ossicles, the amount of circulating cells in the mouse peripheral blood is relatively low and is not reflective of the actual engraftment in the ossicle or the mouse BM.
If leukemia cells are transplanted into humanized ossicles, we reproducibly found that humanized ossicles are superior in supporting leukemic engraftment of primary patient samples bearing diverse genetic lesions 25 . Transplantation of AML blasts leads to fast and fulminant myeloid-restricted engraftment in the ossicle (Fig. 5d) and preferred homing of leukemia cells to other humanized ossicle sites. Notably, when using leukemia samples previously confirmed as low (<1%) or non-engrafters for intraossicle and intravenous transplantation, human chimerism in the humanized BM ossicles usually reaches >90%, whereas human engraftment in the mouse BM remains very low or absent 25 . This and additionally robust engraftment of APL and MF samples confirm the superiority of the presented method, and applying this protocol will allow investigators to substantially extend their repertoire of engraftable primary samples. This humanized BM ossicle xenotransplantation system will not only facilitate in vivo studies of diverse AML subtypes, it will also broadly extend the use of xenotransplantation for in vivo investigation of hematological malignancies other than acute leukemias. coMpetInG FInancIal Interests The authors declare competing financial interests: details are available in the online version of the paper.
